JP2012522001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522001A5 JP2012522001A5 JP2012502246A JP2012502246A JP2012522001A5 JP 2012522001 A5 JP2012522001 A5 JP 2012522001A5 JP 2012502246 A JP2012502246 A JP 2012502246A JP 2012502246 A JP2012502246 A JP 2012502246A JP 2012522001 A5 JP2012522001 A5 JP 2012522001A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- pharmaceutically acceptable
- tlr2
- acceptable composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 28
- 102100012096 TLR2 Human genes 0.000 claims description 17
- 101700064022 TLR2 Proteins 0.000 claims description 17
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 15
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 15
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 8
- 230000000813 microbial Effects 0.000 claims description 8
- 241000191940 Staphylococcus Species 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 244000052616 bacterial pathogens Species 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 241000701242 Adenoviridae Species 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims description 2
- 229940065181 Bacillus anthracis Drugs 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000223203 Coccidioides Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 2
- 229940118764 FRANCISELLA TULARENSIS Drugs 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 241000710781 Flaviviridae Species 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 241000700739 Hepadnaviridae Species 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 241000228402 Histoplasma Species 0.000 claims description 2
- 208000006572 Human Influenza Diseases 0.000 claims description 2
- 206010022000 Influenza Diseases 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 241000588621 Moraxella Species 0.000 claims description 2
- 241000150452 Orthohantavirus Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000233870 Pneumocystis Species 0.000 claims description 2
- 241000711902 Pneumovirus Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 208000003152 Yellow Fever Diseases 0.000 claims description 2
- 229940118695 Yersinia pestis Drugs 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agents Drugs 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 238000002663 nebulization Methods 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 230000000241 respiratory Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 241000335423 Blastomyces Species 0.000 claims 1
- 241000711502 Paramyxovirinae Species 0.000 claims 1
- 208000007089 Vaccinia Diseases 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
Description
[本発明1001]
微生物感染症を有するかまたは発症もしくは獲得する危険性がある個体へ、有効量のTLR9アゴニストおよびTLR2/6アゴニストを投与する工程を含む、微生物感染症を治療、抑制または軽減する方法。
[本発明1002]
TLR2/6アゴニストがPAM2CSK4である、本発明1001の方法。
[本発明1003]
TLR9アゴニストがC型オリゴデオキシヌクレオチド（ODN）である、本発明1001の方法。
[本発明1004]
C型ODNがODN2395またはODN M362またはODN10101である、本発明1003の方法。
[本発明1005]
被験体が病原性微生物へ曝露されている、本発明1001の方法。
[本発明1006]
微生物が、ウイルス、細菌、または真菌である、本発明1001の方法。
[本発明1007]
ウイルスが、アデノウイルス科、コロナウイルス科、フィロウイルス科、フラビウイルス科、ヘパドナウイルス科、ヘルペスウイルス科、オルトミクソウイルス科、パラミクソウイルス亜科、ニューモウイルス亜科、ピコルナウイルス科、ポックスウイルス科（Poxyiridae）、レトロウイルス科、トガウイルス科、パラインフルエンザ、インフルエンザ、H5N1、マールブルグ、エボラ、重症急性呼吸器症候群コロナウイルス、黄熱、ヒト呼吸器合胞体、ハンタウイルス、またはワクシニアウイルスである、本発明1006の方法。
[本発明1008]
細菌が、炭疽菌（Bacillus anthracis）、ペスト菌（Yersinia pestis）、野兎病菌（Francisella tularensis）、緑膿菌（Pseudomonas aerugenosa）、黄色ブドウ球菌（Staphylococcus aureas）、スタフィロコッカス・ニューモニア（Staphylococcus pneumonia）、スタフィロコッカス・マルトフィリア（Staphlyococcus maltophilia）、バークホルデリア種（Burholderia spp.）またはモラクセラ種（Moraxella spp）である、本発明1006の方法。
[本発明1009]
真菌が、アスペルギルス属、カンジダ属、クリプトコッカス属、ヒストプラズマ属、コクシジオイデス属、ブラストミセス属、接合菌類（Zygometes）、またはニューモシスティス属である、本発明1006の方法。
[本発明1010]
TLR9アゴニストおよびTLR2/6アゴニストを噴霧化製剤で投与する、本発明1001の方法。
[本発明1011]
有効量のTLR9アゴニストおよびTLR2/6アゴニストを個体の肺内に沈着(deposit)させる、本発明1001の方法。
[本発明1012]
TLR9アゴニストおよびTLR2/6アゴニストを、約0.1 mg／個体体重のkg〜約100 mg／個体体重のkgの量で投与する、本発明1001の方法。
[本発明1013]
TLR9アゴニストおよびTLR2/6アゴニスト、抗炎症剤、ならびに1つまたは複数の薬学的賦形剤を含む薬学的に許容される組成物であって、無菌でありかつ病原性微生物を本質的に含まない、前記組成物。
[本発明1014]
組成物が、噴霧療法用に処方されている、本発明1013の組成物。
[本発明1015]
TLR2/6アゴニストがPAM2CSK4である、本発明1013の組成物。
[本発明1016]
TLR9アゴニストがC型オリゴデオキシヌクレオチド（ODN）である、本発明1013の組成物。
[本発明1017]
C型ODNがODN2395またはODN M362またはODN10101である、本発明1013の組成物。
下記の図面は、本明細書の一部分を形成し、本発明のある局面をさらに示すために含まれる。本発明は、本明細書に示される具体的な態様の詳細な説明と組み合わせてこれらの図面の1つまたは複数を参照することによって、よりよく理解され得る。
微生物感染症を有するかまたは発症もしくは獲得する危険性がある個体へ、有効量のTLR9アゴニストおよびTLR2/6アゴニストを投与する工程を含む、微生物感染症を治療、抑制または軽減する方法。
[本発明1002]
TLR2/6アゴニストがPAM2CSK4である、本発明1001の方法。
[本発明1003]
TLR9アゴニストがC型オリゴデオキシヌクレオチド（ODN）である、本発明1001の方法。
[本発明1004]
C型ODNがODN2395またはODN M362またはODN10101である、本発明1003の方法。
[本発明1005]
被験体が病原性微生物へ曝露されている、本発明1001の方法。
[本発明1006]
微生物が、ウイルス、細菌、または真菌である、本発明1001の方法。
[本発明1007]
ウイルスが、アデノウイルス科、コロナウイルス科、フィロウイルス科、フラビウイルス科、ヘパドナウイルス科、ヘルペスウイルス科、オルトミクソウイルス科、パラミクソウイルス亜科、ニューモウイルス亜科、ピコルナウイルス科、ポックスウイルス科（Poxyiridae）、レトロウイルス科、トガウイルス科、パラインフルエンザ、インフルエンザ、H5N1、マールブルグ、エボラ、重症急性呼吸器症候群コロナウイルス、黄熱、ヒト呼吸器合胞体、ハンタウイルス、またはワクシニアウイルスである、本発明1006の方法。
[本発明1008]
細菌が、炭疽菌（Bacillus anthracis）、ペスト菌（Yersinia pestis）、野兎病菌（Francisella tularensis）、緑膿菌（Pseudomonas aerugenosa）、黄色ブドウ球菌（Staphylococcus aureas）、スタフィロコッカス・ニューモニア（Staphylococcus pneumonia）、スタフィロコッカス・マルトフィリア（Staphlyococcus maltophilia）、バークホルデリア種（Burholderia spp.）またはモラクセラ種（Moraxella spp）である、本発明1006の方法。
[本発明1009]
真菌が、アスペルギルス属、カンジダ属、クリプトコッカス属、ヒストプラズマ属、コクシジオイデス属、ブラストミセス属、接合菌類（Zygometes）、またはニューモシスティス属である、本発明1006の方法。
[本発明1010]
TLR9アゴニストおよびTLR2/6アゴニストを噴霧化製剤で投与する、本発明1001の方法。
[本発明1011]
有効量のTLR9アゴニストおよびTLR2/6アゴニストを個体の肺内に沈着(deposit)させる、本発明1001の方法。
[本発明1012]
TLR9アゴニストおよびTLR2/6アゴニストを、約0.1 mg／個体体重のkg〜約100 mg／個体体重のkgの量で投与する、本発明1001の方法。
[本発明1013]
TLR9アゴニストおよびTLR2/6アゴニスト、抗炎症剤、ならびに1つまたは複数の薬学的賦形剤を含む薬学的に許容される組成物であって、無菌でありかつ病原性微生物を本質的に含まない、前記組成物。
[本発明1014]
組成物が、噴霧療法用に処方されている、本発明1013の組成物。
[本発明1015]
TLR2/6アゴニストがPAM2CSK4である、本発明1013の組成物。
[本発明1016]
TLR9アゴニストがC型オリゴデオキシヌクレオチド（ODN）である、本発明1013の組成物。
[本発明1017]
C型ODNがODN2395またはODN M362またはODN10101である、本発明1013の組成物。
下記の図面は、本明細書の一部分を形成し、本発明のある局面をさらに示すために含まれる。本発明は、本明細書に示される具体的な態様の詳細な説明と組み合わせてこれらの図面の1つまたは複数を参照することによって、よりよく理解され得る。
Claims (15)
- TLR9アゴニストを含む、微生物感染症を有するかまたは発症もしくは獲得する危険性がある個体における微生物感染症を治療、抑制または軽減するための薬学的に許容される組成物であって、合成ジアシル化リポポリペプチドであるTLR2/6アゴニストと組み合わせて使用される、前記組成物。
- 合成ジアシル化リポポリペプチドであるTLR2/6アゴニストを含む、微生物感染症を有するかまたは発症もしくは獲得する危険性がある個体における微生物感染症を治療、抑制または軽減するための薬学的に許容される組成物であって、TLR9アゴニストと組み合わせて使用される、前記組成物。
- TLR9アゴニストおよびTLR2/6アゴニストを含む、微生物感染症を有するかまたは発症もしくは獲得する危険性がある個体における微生物感染症を治療、抑制または軽減するための薬学的に許容される組成物であって、該TLR2/6アゴニストが合成ジアシル化リポポリペプチドである、前記組成物。
- TLR2/6アゴニストがPAM2CSK4である、請求項１〜３のいずれか１項記載の薬学的に許容される組成物。
- TLR9アゴニストがC型オリゴデオキシヌクレオチド（ODN）である、請求項１〜４のいずれか１項記載の薬学的に許容される組成物。
- C型ODNがODN2395またはODN M362またはODN10101である、請求項５記載の薬学的に許容される組成物。
- 個体が病原性微生物へ曝露されている、請求項１〜６のいずれか１項記載の薬学的に許容される組成物。
- 微生物が、ウイルス、細菌、または真菌である、請求項１〜７のいずれか１項記載の薬学的に許容される組成物。
- （ａ）ウイルスが、アデノウイルス科、コロナウイルス科、フィロウイルス科、フラビウイルス科、ヘパドナウイルス科、ヘルペスウイルス科、オルトミクソウイルス科、パラミクソウイルス亜科、ニューモウイルス亜科、ピコルナウイルス科、ポックスウイルス科（Poxyiridae）、レトロウイルス科、トガウイルス科、パラインフルエンザ、インフルエンザ、H5N1、マールブルグ、エボラ、重症急性呼吸器症候群コロナウイルス、黄熱、ヒト呼吸器合胞体、ハンタウイルス、もしくはワクシニアウイルスであるか、
（ｂ）細菌が、炭疽菌（Bacillus anthracis）、ペスト菌（Yersinia pestis）、野兎病菌（Francisella tularensis）、緑膿菌（Pseudomonas aerugenosa）、黄色ブドウ球菌（Staphylococcus aureas）、スタフィロコッカス・ニューモニア（Staphylococcus pneumonia）、スタフィロコッカス・マルトフィリア（Staphlyococcus maltophilia）、バークホルデリア種（Burholderia spp.）もしくはモラクセラ種（Moraxella spp）であるか、または
（ｃ）真菌が、アスペルギルス属、カンジダ属、クリプトコッカス属、ヒストプラズマ属、コクシジオイデス属、ブラストミセス属、接合菌類（Zygometes）、もしくはニューモシスティス属である、
請求項８記載の薬学的に許容される組成物。 - 有効量のTLR9アゴニストおよびTLR2/6アゴニストを個体の肺内に沈着(deposit)させる、請求項１〜９のいずれか１項記載の薬学的に許容される組成物。
- TLR9アゴニストおよびTLR2/6アゴニストが、約0.1 mg／個体体重のkg〜約100 mg／個体体重のkgの量で投与される、請求項１〜１０のいずれか１項記載の薬学的に許容される組成物。
- TLR9アゴニストおよびTLR2/6アゴニスト、抗炎症剤、ならびに1つまたは複数の薬学的賦形剤を含む薬学的に許容される組成物であって、無菌でありかつ病原性微生物を本質的に含まず、該TLR2/6アゴニストが合成ジアシル化リポポリペプチドである、前記組成物。
- 組成物が、噴霧療法用に処方されている、請求項１〜１２のいずれか１項記載の薬学的に許容される組成物。
- TLR2/6アゴニストがPAM2CSK4であるか、または
TLR9アゴニストがC型オリゴデオキシヌクレオチド（ODN）である、
請求項１３記載の薬学的に許容される組成物。 - C型ODNがODN2395またはODN M362またはODN10101である、請求項１４記載の薬学的に許容される組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16313709P | 2009-03-25 | 2009-03-25 | |
| US61/163,137 | 2009-03-25 | ||
| US17924609P | 2009-05-18 | 2009-05-18 | |
| US61/179,246 | 2009-05-18 | ||
| PCT/US2010/028658 WO2010111485A1 (en) | 2009-03-25 | 2010-03-25 | Compositions for stimulation of mammalian innate immune resistance to pathogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015114466A Division JP6084655B2 (ja) | 2009-03-25 | 2015-06-05 | 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522001A JP2012522001A (ja) | 2012-09-20 |
| JP2012522001A5 true JP2012522001A5 (ja) | 2013-04-18 |
| JP5759445B2 JP5759445B2 (ja) | 2015-08-05 |
Family
ID=42237276
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502246A Active JP5759445B2 (ja) | 2009-03-25 | 2010-03-25 | 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物 |
| JP2015114466A Active JP6084655B2 (ja) | 2009-03-25 | 2015-06-05 | 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015114466A Active JP6084655B2 (ja) | 2009-03-25 | 2015-06-05 | 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8883174B2 (ja) |
| EP (1) | EP2411521B1 (ja) |
| JP (2) | JP5759445B2 (ja) |
| KR (2) | KR101856462B1 (ja) |
| CN (3) | CN103800906B (ja) |
| AU (1) | AU2010229835B2 (ja) |
| BR (1) | BRPI1009842B8 (ja) |
| CA (2) | CA3033133C (ja) |
| ES (1) | ES2534947T3 (ja) |
| HK (1) | HK1217176A1 (ja) |
| IL (2) | IL215288A (ja) |
| MX (1) | MX2011010050A (ja) |
| PL (1) | PL2411521T3 (ja) |
| PT (1) | PT2411521E (ja) |
| WO (1) | WO2010111485A1 (ja) |
| ZA (1) | ZA201107774B (ja) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2411521T3 (pl) * | 2009-03-25 | 2015-08-31 | Univ Texas | Kompozycje do stymulacji wrodzonej odporności immunologicznej na patogeny u ssaków |
| JP2012523379A (ja) | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| EP3669892B1 (en) | 2010-09-22 | 2024-05-08 | ENA Respiratory Pty Ltd | Composition for use in a immunostimulatory method |
| US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| CA2950293A1 (en) * | 2014-06-02 | 2015-12-10 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
| US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| KR102515202B1 (ko) * | 2016-11-09 | 2023-03-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 후천성 면역 조절을 위한 방법 및 조성물 |
| JP6750468B2 (ja) * | 2016-11-18 | 2020-09-02 | アイシン精機株式会社 | 内燃機関 |
| KR20200031144A (ko) | 2017-07-20 | 2020-03-23 | 스포겐 바이오테크 인코포레이티드 | 식물 보호, 성장 및 생산성 향상을 위한 생물활성 폴리펩타이드 |
| CN108739670A (zh) * | 2018-09-04 | 2018-11-06 | 乡宁县关王庙乡新杰养羊专业合作社 | 一种防治羊肾炎的方法 |
| MX2022005633A (es) * | 2020-01-10 | 2022-06-14 | Sbi Biotech Co Ltd | Novedosos agonistas del receptor tipo toll 9 (tlr9). |
| US20210317454A1 (en) * | 2020-04-10 | 2021-10-14 | Idera Pharmaceuticals, Inc. | Use of a tlr9 agonist in methods for treating covid-19 |
| US20230226004A1 (en) * | 2020-05-26 | 2023-07-20 | Axelia Oncology Pty Ltd | Treatment of coronavirus |
| CN113234130A (zh) * | 2021-05-24 | 2021-08-10 | 安徽医科大学第四附属医院 | 一种卡氏肺孢子菌重组蛋白及其制备方法与应用 |
Family Cites Families (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7461M (ja) | 1968-06-19 | 1970-01-05 | ||
| EP0014815A3 (de) | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
| FI75578C (fi) | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider. |
| US4406889A (en) | 1980-02-15 | 1983-09-27 | Ciba-Geigy Corporation | Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GR78246B (ja) | 1981-01-23 | 1984-09-26 | Ciba Geigy Ag | |
| EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US6024964A (en) | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| DE4119856A1 (de) | 1991-06-17 | 1992-12-24 | Hoechst Ag | N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen |
| DE69233690T2 (de) | 1991-07-02 | 2008-01-24 | Nektar Therapeutics, San Carlos | Abgabevorrichtung für nebelförmige Medikamente |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
| BR9307270A (pt) | 1992-10-19 | 1999-06-01 | Dura Pharma Inc | Inalador de pó seco |
| JP3549533B2 (ja) | 1993-01-19 | 2004-08-04 | グラクソ、グループ、リミテッド | 装置 |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| EP0622375A1 (de) | 1993-02-20 | 1994-11-02 | Hoechst Aktiengesellschaft | Chrysospermine, Peptidwirkstoffe aus Apiocrea chrysosperma mit pharmakologischer Wirkung, ein Verfahren zu Herstellung und Verwendung derselben |
| US6288042B1 (en) | 1993-04-23 | 2001-09-11 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich tetrad forming oligonucleotides |
| US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| WO1995002597A1 (en) | 1993-07-15 | 1995-01-26 | Minnesota Mining And Manufacturing Company | IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| ATE222921T1 (de) | 1994-01-26 | 2002-09-15 | Novartis Erfind Verwalt Gmbh | Modifizierte oligonukleotide |
| WO1995024183A1 (en) | 1994-03-07 | 1995-09-14 | Inhale Therapeutic Systems | Methods and compositions for pulmonary delivery of insulin |
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| CA2241880A1 (en) | 1996-01-03 | 1997-07-17 | Glaxo Group Limited | Inhalation device |
| US6294177B1 (en) | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
| DE19642014B4 (de) | 1996-10-11 | 2005-08-04 | Pactec Verpackungsmaschinen-Fabrik Theegarten Gmbh & Co. Kg | Vorrichtung zum Verpacken kleinstückiger Artikel im Falteinschlag |
| KR100518903B1 (ko) | 1996-10-25 | 2005-10-06 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물 |
| EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP0981625A2 (en) | 1997-05-06 | 2000-03-01 | Human Genome Sciences, Inc. | $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES |
| WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| EP0986572B2 (en) | 1997-06-06 | 2007-06-13 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US6517839B1 (en) | 1997-07-18 | 2003-02-11 | The Regents Of The University Of California | Methods for inducing interleukin-12 and a type1/Th1 T-cell response |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| AU760795B2 (en) | 1998-05-14 | 2003-05-22 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
| GB9905538D0 (en) | 1999-03-10 | 1999-05-05 | Glaxo Group Ltd | A device |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| EP1700603A3 (en) | 1999-09-25 | 2007-06-13 | Coley Pharmaceutical GmbH | Immunostimulatory nucleic acids |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| DE60131430T2 (de) | 2000-01-14 | 2008-10-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
| JP4443810B2 (ja) | 2000-01-26 | 2010-03-31 | イデラ ファーマシューティカルズ インコーポレイテッド | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 |
| WO2001055341A2 (en) | 2000-01-31 | 2001-08-02 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| CA2404041A1 (en) | 2000-03-28 | 2001-10-04 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
| KR100875003B1 (ko) | 2000-05-01 | 2008-12-19 | 이데라 파마슈티칼즈, 인코포레이티드 | 누클레오시드의 위치 변형에 의한 올리고누클레오티드 ＣｐＧ 매개성 면역 자극의 조절 |
| CA2410371C (en) | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| JP2005500806A (ja) | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| ATE398175T1 (de) | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US20050287612A1 (en) | 2000-12-29 | 2005-12-29 | John Bertin | CARD-4 molecules and uses thereof |
| US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| ES2421532T3 (es) | 2001-06-21 | 2013-09-03 | Dynavax Tech Corp | Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos |
| US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| EP1412390A2 (en) | 2001-07-26 | 2004-04-28 | Tanox, Inc. | Agents that activate or inhibit toll-like receptor 9 |
| CA2457485C (en) | 2001-08-17 | 2012-08-14 | Arthur M. Krieg | Combination motif immune stimulatory oligonucleotides with improved activity |
| AU2002353783A1 (en) | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| AU2002360278A1 (en) | 2001-10-12 | 2003-11-11 | Coley Pharmaceutical Gmbh | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| CA2476405C (en) | 2002-02-13 | 2011-10-11 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
| US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| US7371734B2 (en) | 2002-04-22 | 2008-05-13 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use for the modulation of immune responses |
| KR100456681B1 (ko) | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물 |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| US20040009949A1 (en) | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
| AU2003299863B2 (en) | 2002-08-15 | 2009-09-24 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| CA2498777C (en) | 2002-09-13 | 2015-01-13 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
| SI2241325T1 (sl) | 2002-10-29 | 2012-05-31 | Coley Pharm Group Inc | Uporaba CPG oligonukleotidov pri zdravljenju okužbe z virusom hepatitisa C |
| WO2004041183A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
| US7491395B2 (en) | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| DE60333786D1 (de) | 2002-11-21 | 2010-09-23 | Univ R | Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| AU2003300184B8 (en) * | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
| US20040259790A1 (en) * | 2003-01-30 | 2004-12-23 | Bali Pulendran | Methods for identifying and administering agents that bias the immune response via dendritic cells |
| HUE026171T2 (en) | 2003-02-03 | 2016-05-30 | Cerebus Biologicals Inc | A method for treating, preventing and detecting Helicobacter infection |
| EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
| WO2004075865A2 (en) | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
| CA2521050A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| CA2525464A1 (en) | 2003-05-12 | 2004-11-25 | Qun Yin | Novel poly(ethylene glycol) modified compounds and uses thereof |
| WO2004110992A2 (en) | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | Process for imidazo[4,5-c] pyridin-4-amines |
| CN102604957B (zh) | 2003-06-11 | 2015-10-07 | 艾德拉药物股份有限公司 | 稳定的免疫调节寡核苷酸 |
| AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
| US20050013812A1 (en) | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| WO2005009355A2 (en) | 2003-07-15 | 2005-02-03 | Hybridon, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| KR101146203B1 (ko) | 2003-07-25 | 2012-05-25 | 창춘 후아푸 바이오테크놀로지 씨오., 엘티디. | 인공합성한 ＣｐＧ 단일가닥 올리고데옥시뉴클레오티드 및이의 항바이러스 용도 |
| JP2007502288A (ja) | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | オキシム置換イミダゾ含有化合物 |
| CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
| WO2005030133A2 (en) | 2003-09-22 | 2005-04-07 | Yale University | Treatment with agonists of toll-like receptors |
| US7615539B2 (en) | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| DE602004027940D1 (de) | 2003-10-22 | 2010-08-12 | Id Biomedical Corp Quebec | Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| US7202234B2 (en) | 2003-10-24 | 2007-04-10 | Eisai Co., Ltd. | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions |
| AP2006003611A0 (en) * | 2003-10-30 | 2006-06-30 | Coley Pharm Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| US20050100983A1 (en) | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| JP2007511535A (ja) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ環化合物 |
| US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
| KR101138131B1 (ko) | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
| WO2005072088A2 (en) | 2003-12-11 | 2005-08-11 | Sciperio, Inc. | Immunotherapy compositions, method of making and method of use thereof |
| EP1550458A1 (en) * | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
| US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
| JP2007517055A (ja) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答の増強 |
| KR100558851B1 (ko) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체 |
| EP2415481A3 (en) | 2004-02-19 | 2012-04-18 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
| JP2007523173A (ja) | 2004-02-20 | 2007-08-16 | イデラ ファーマシューティカルズ インコーポレイテッド | 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答 |
| US20060019916A1 (en) | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
| US20080113929A1 (en) | 2004-06-08 | 2008-05-15 | Coley Pharmaceutical Gmbh | Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist |
| US7427405B2 (en) | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| ES2645158T3 (es) | 2004-06-15 | 2017-12-04 | Idera Pharmaceuticals, Inc. | Multímeros de oligonucleótidos inmunoestimuladores |
| US7425548B2 (en) | 2004-07-09 | 2008-09-16 | Variety Chidren's Hospital | Materials and methods for immune system stimulation |
| WO2007026190A2 (en) | 2004-07-18 | 2007-03-08 | Csl Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| WO2006029223A2 (en) | 2004-09-08 | 2006-03-16 | Children's Medical Center Corporation | Method for stimulating the immune response of newborns |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| AU2005311888A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| WO2006065751A2 (en) | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
| WO2006073940A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | Multi-route administration of immune response modifier compounds |
| JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物 |
| CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| JP5122980B2 (ja) | 2005-02-09 | 2013-01-16 | スリーエム イノベイティブ プロパティズ カンパニー | アルキルオキシ置換チアゾロキノリン類およびアルキルオキシ置換チアゾロナフチリデン類 |
| CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| EP1858326A4 (en) * | 2005-02-22 | 2008-10-15 | Univ California | METHODS OF TREATING GASTROINTESTINAL INFLAMMATION |
| US8343993B2 (en) | 2005-02-23 | 2013-01-01 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazonaphthyridines |
| JP2008538203A (ja) | 2005-02-23 | 2008-10-16 | コーリー ファーマシューティカル グループ，インコーポレイテッド | インターフェロンの生合成を優先的に誘導する方法 |
| AU2006216798A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| JP2008543725A (ja) | 2005-02-23 | 2008-12-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ヒドロキシアルキル置換イミダゾキノリン |
| CN101160401A (zh) | 2005-02-24 | 2008-04-09 | 科勒制药集团公司 | 免疫刺激寡核苷酸 |
| JP2008535832A (ja) | 2005-04-01 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ピラゾロピリジン−１，４−ジアミン、およびそのアナログ |
| US8138173B2 (en) | 2005-04-01 | 2012-03-20 | 3M Innovative Properties Company | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods |
| WO2006107851A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| JP2008535859A (ja) | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
| AR056327A1 (es) | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
| WO2006116458A2 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
| AU2006257383A1 (en) | 2005-06-16 | 2006-12-21 | Universiteit Gent | Vaccines for immunization against Helicobacter |
| US20090220528A1 (en) | 2005-06-17 | 2009-09-03 | The Trustees Of The Univeristy Of Pennsylvania Cneter For Technology Transfer | Stimulation of Toll-Like Receptors on T Cells |
| WO2007008463A2 (en) | 2005-07-07 | 2007-01-18 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| EP1929014B1 (en) | 2005-08-31 | 2014-08-13 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Methods of altering an immune response induced by d-type cpg oligodeoxynucleotides |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| WO2007031322A1 (en) | 2005-09-14 | 2007-03-22 | Gunther Hartmann | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides |
| WO2007088423A2 (en) | 2005-09-16 | 2007-08-09 | Coley Pharmaceutical Gmbh | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
| KR20080047463A (ko) | 2005-09-16 | 2008-05-28 | 콜리 파마슈티칼 게엠베하 | 뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절 |
| US8399423B2 (en) | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| CN104278037B (zh) | 2005-10-12 | 2020-09-15 | 艾德拉药物股份有限公司 | 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物 |
| US8426375B2 (en) | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| PL1957647T3 (pl) | 2005-11-25 | 2015-07-31 | Zoetis Belgium S A | Oligorybonukleotydy immunostymulujące |
| CA2632943A1 (en) | 2005-12-20 | 2007-07-26 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of toll-like receptors containing cg dinucleotide modifications |
| JP2009521218A (ja) | 2005-12-20 | 2009-06-04 | イデラ ファーマシューティカルズ インコーポレイテッド | 異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド（ｉｍｏ（ｔｍ））の免疫賦活作用 |
| US20080045473A1 (en) | 2006-02-15 | 2008-02-21 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
| ES2564303T3 (es) | 2006-04-07 | 2016-03-21 | Idera Pharmaceuticals, Inc. | Compuestos de ARN inmunomodulador estabilizado (SIMRA) para TLR7 y TLR8 |
| US20090176696A1 (en) | 2006-04-18 | 2009-07-09 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth | Methods And Compositions For Modulating An Immune Response |
| WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| US20080170996A1 (en) | 2006-07-28 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and Methods for Stimulation of Lung Innate Immunity |
| US20080124366A1 (en) | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US20080241139A1 (en) | 2006-10-31 | 2008-10-02 | Regents Of The University Of Colorado | Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity |
| US20090142362A1 (en) | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
| JP2010510223A (ja) * | 2006-11-15 | 2010-04-02 | サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド | Ｔｉｍ−３調節物質の治療的使用 |
| JP2010512421A (ja) | 2006-12-12 | 2010-04-22 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の合成アゴニスト |
| WO2008131074A1 (en) | 2007-04-19 | 2008-10-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
| WO2009015107A1 (en) | 2007-07-20 | 2009-01-29 | Yeda Research And Development Co. Ltd. | Modulation of toll-like receptors for controlling neurogenesis |
| AU2008282172B2 (en) | 2007-08-01 | 2014-05-22 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of TLR9 |
| WO2009022215A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| JP2010536787A (ja) | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様受容体モジュレータ |
| US9421254B2 (en) | 2007-09-24 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunostimulatory combinations of TLR ligands and methods of use |
| US9872867B2 (en) | 2008-06-06 | 2018-01-23 | Tanya Kuritz | Methods and compositions for modulation of innate immunity |
| PL2411521T3 (pl) * | 2009-03-25 | 2015-08-31 | Univ Texas | Kompozycje do stymulacji wrodzonej odporności immunologicznej na patogeny u ssaków |
-
2010
- 2010-03-25 PL PL10716433T patent/PL2411521T3/pl unknown
- 2010-03-25 KR KR1020177010287A patent/KR101856462B1/ko active IP Right Grant
- 2010-03-25 CN CN201310588997.2A patent/CN103800906B/zh active Active
- 2010-03-25 CA CA3033133A patent/CA3033133C/en active Active
- 2010-03-25 KR KR1020117025110A patent/KR101730351B1/ko active IP Right Grant
- 2010-03-25 EP EP20100716433 patent/EP2411521B1/en active Active
- 2010-03-25 AU AU2010229835A patent/AU2010229835B2/en active Active
- 2010-03-25 CN CN201080022634.7A patent/CN102439153B/zh active Active
- 2010-03-25 MX MX2011010050A patent/MX2011010050A/es active IP Right Grant
- 2010-03-25 CN CN201510337464.6A patent/CN105126072B/zh active Active
- 2010-03-25 ES ES10716433.7T patent/ES2534947T3/es active Active
- 2010-03-25 JP JP2012502246A patent/JP5759445B2/ja active Active
- 2010-03-25 BR BRPI1009842A patent/BRPI1009842B8/pt active IP Right Grant
- 2010-03-25 CA CA2756412A patent/CA2756412C/en active Active
- 2010-03-25 WO PCT/US2010/028658 patent/WO2010111485A1/en active Application Filing
- 2010-03-25 PT PT107164337T patent/PT2411521E/pt unknown
- 2010-03-25 US US13/259,761 patent/US8883174B2/en active Active
-
2011
- 2011-09-21 IL IL215288A patent/IL215288A/en active IP Right Grant
- 2011-10-24 ZA ZA2011/07774A patent/ZA201107774B/en unknown
-
2014
- 2014-10-21 US US14/519,834 patent/US9186400B2/en active Active
-
2015
- 2015-06-05 JP JP2015114466A patent/JP6084655B2/ja active Active
- 2015-07-28 IL IL240202A patent/IL240202A0/en active IP Right Grant
- 2015-09-23 US US14/862,884 patent/US9504742B2/en active Active
-
2016
- 2016-05-06 HK HK16105189.2A patent/HK1217176A1/zh unknown
- 2016-11-18 US US15/355,530 patent/US10722573B2/en active Active
-
2020
- 2020-07-24 US US16/937,967 patent/US20200345842A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522001A5 (ja) | ||
| JP2015199747A5 (ja) | ||
| Andrade et al. | Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases | |
| Chen et al. | Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice | |
| CA2604392A1 (en) | Quaternary ammonium halides for treatment of infectious conditions | |
| JP2010132695A5 (ja) | ||
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| JP2010285436A5 (ja) | ||
| AU2019100465B4 (en) | Treatment and prevention of the common cold using povidone-iodine | |
| Holle et al. | Nebulized voriconazole in infections with Scedosporium apiospermum—case report and review of the literature | |
| García et al. | Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution | |
| Oxford et al. | Targeting influenza virus neuraminidase—a new strategy for antiviral therapy | |
| ES2928399T3 (es) | Composición farmacéutica bactericida que comprende ibuprofeno | |
| Chen et al. | Efficacy and Safety of Mepolizumab as an Add-on Therapy in Chinese Patients With Severe Eosinophilic Asthma: A Randomized, Double-Blind, Parallel Group Phase 3 Study | |
| Conrad et al. | Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection | |
| Khalil et al. | Povidone Iodine (PVP-I) mouth gargle/nasal spray may be the simplest and cost effective therapeutic antidote for COVID-19 Frontier | |
| JP2011006424A5 (ja) | ||
| Sabracos et al. | The in vitro effective antiviral action of povidone–iodine (PVP–I) may also have therapeutic potential by its intravenous administration diluted with Ringer’s solution | |
| Ottaviano et al. | Myriocin ameliorates defective killing of pathogens in cystic fibrosis patients | |
| Herrmann et al. | 113 Inhalative meropenem–tobramycin–colistin combination improves lung function in chronic Pseudomonas aeruginosa colonization | |
| Zachar | Inhalation Formulation & Dosage of PVP Iodine for Respiratory Infections Treatment | |
| Lu et al. | Assessment of Efficiency of Nebulized Ceftazidime and Amikacine in Patients with Pneumonia Caused by Pseudomonas aeruginosa. | |
| WO2022079498A1 (en) | Composition for the prevention of infection by sars-cov-2 | |
| Kennedy et al. | 114 Investigating the activity of antibiotics at aerosolized concentrations against Burkholderia cepacia complex biofilms | |
| Hurley et al. | 115 Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis–Cochrane review |